These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1869342)

  • 41. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2013 Dec; 34(9):527-39. PubMed ID: 24123104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of etoricoxib in patients with renal impairment.
    Agrawal NG; Matthews CZ; Mazenko RS; Kline WF; Woolf EJ; Porras AG; Geer LA; Wong PH; Cho M; Cote J; Marbury TC; Moncrief JW; Alcorn H; Swan S; Sack MR; Robson RA; Petty KJ; Schwartz JI; Gottesdiener KM
    J Clin Pharmacol; 2004 Jan; 44(1):48-58. PubMed ID: 14681341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers.
    Wootton R; Soul-Lawton J; Rolan PE; Sheung CT; Cooper JD; Posner J
    Br J Clin Pharmacol; 1997 Jan; 43(1):23-7. PubMed ID: 9056048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
    Randinitis EJ; Posvar EL; Alvey CW; Sedman AJ; Cook JA; Bockbrader HN
    J Clin Pharmacol; 2003 Mar; 43(3):277-83. PubMed ID: 12638396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
    Lameire N; Rosenkranz B; Maass L; Brockmeier D
    Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.
    Lecaillon JB; Dubois JP; Coppens H; Darragon T; Reumond G; Pozet N; Traeger J; Lambrey G
    Eur J Drug Metab Pharmacokinet; 1990; 15(3):231-7. PubMed ID: 2253654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
    Granneman GR; Braeckman R; Kraut J; Shupien S; Craft JC
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2345-51. PubMed ID: 1666497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose dependency in the gastrointestinal absorption of cefatrizine: correlation between in vivo and in situ.
    Matsuda K; Yuasa H; Watanabe J
    Biol Pharm Bull; 1998 Jun; 21(6):604-9. PubMed ID: 9657046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vancomycin pharmacokinetics in patients with various degrees of renal function.
    Rodvold KA; Blum RA; Fischer JH; Zokufa HZ; Rotschafer JC; Crossley KB; Riff LJ
    Antimicrob Agents Chemother; 1988 Jun; 32(6):848-52. PubMed ID: 3415206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ethambutol kinetics in patients with impaired renal function.
    Varughese A; Brater DC; Benet LZ; Lee CS
    Am Rev Respir Dis; 1986 Jul; 134(1):34-8. PubMed ID: 3729159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.